Evolving Treatment Strategies in the
Management of Hyperkalemia: Managed Care Considerations for Improved
Clinical and Economic Outcomes
A continuing medical education
activity provided by NAMCP and AAMCN
This activity is an archive from the live session from the 2022
Fall Managed Care Forum. If you participated in the live session,
you are not eligible for continuing education credits from this
This activity is valid from March 1, 2023 to March 1, 2024
Instructions for CME/NCPD: Complete the pre-test, listen to the
audio and view the slides, complete the post test, complete the
evaluation form and hit submit. You will be asked to enter your name
and email address on the pre-test, evaluation and post-test. If you
close your internet browser without completing the post test, you
will have ONE more opportunity to complete. A score of 70% must be
achieved on the post test to receive continuing education credits.
If you do not pass the post test after two attempts, you will not be
eligible to try again. Once you complete the evaluation form and
score 70% or higher on your post test, you will automatically be
given your certificate.
To print or save your certificate, you will need to click on the
“download” button and either print or save.
This activity is intended for healthcare professionals practicing in
managed care environments.
This activity is supported by
an educational grant from
Hyperkalemia, also known has high potassium, is an elevated level of
potassium in the blood. Normal potassium levels are between 3.5 and
5.0 mmol/L with levels above 5.5 mmol/L defined as hyperkalemia.
Typically, this results in no symptoms, but occasionally when severe
it results in palpitations, muscle pain, muscle weakness, or
numbness. Decreased kidney function is a major cause of hyperkalemia,
especially in chronic kidney disease (CKD), hypertension, and heart
failure. Chronic hyperkalemia is a challenging clinical problem
associated with increased mortality in patients with CKD and HF. The
risk of hyperkalemia is also a limiting factor in using
renin-angiotensin aldosterone system (RAAS) inhibitors for the
treatment of hypertension, chronic kidney disease, heart failure,
and diabetes. Hyperkalemia occurs in up to 10% of hospitalized
patients and is associated increased morbidity if left unaddressed.
Fortunately for patients who experience hyperkalemia, new therapies
have become available in recent years that have shown improved
efficacy and safety in lowering potassium levels and improving
patient outcomes. Additionally, some of these options have shown the
ability in recent clinical trials to reduce arrhythmia-related
cardiovascular outcomes in patients’ hyperkalemia.
Upon completion of this
activity, participants will be able to:
Assess the clinical and economic
burden of hyperkalemia and the impact of suboptimal management
Explain the importance of a healthy
diet in a patient with hyperkalemia and the quality-of-life
impact of potassium-restricted diet
Compare and contrast the safety,
efficacy, labeling, dosing and role of potassium binders in the
management of hyperkalemia in a variety of settings and
Analyze the emerging role of
potassium binders to reduce arrhythmia-related cardiovascular
outcomes in patients with hyperkalemia
Identify patients with hyperkalemia
with end stage renal disease who would potentially benefit from
a novel potassium binder therapy
Integrate the latest clinical and
pharmacoeconomic data on potassium binders into evidence-based
formulary decisions and benefits design
||Gary Owens, MD
Gary Owens Associates
|(Relevant Financial Relationships with Ineligible
Companies in the Last 24 Months):
Dr. Owens has no relevant financial relationship with an
ineligible company to disclose.
Williams, MD has no relevant financial relationships
with an ineligible company in the last 24 months to
Jeremy Williams has no relevant financial relationships
with an ineligible company in the last 24 months to
Jacqueline Cole, RN, MS, CMCN has no relevant financial
relationships with an ineligible company in the last 24
months to disclose.
NAMCP and/or the presenter
has copyright or has received permissions for use of
materials provided in this activity.
Accreditation & Designation
This activity has been planned and implemented in accordance with
the accreditation requirements and policies of the Accreditation
Council for Continuing Medical Education (ACCME) through the joint
providership of the National Association of Managed Care Physicians
(NAMCP) and American Association of Managed Care Nurses (AAMCN). The
National Association of Managed Care Physicians is accredited by the
ACCME to provide continuing medical education for physicians.
NAMCP designates this enduring material for a maximum of 1 AMA
PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their
participation in the activity.
The American Association of Managed Care Nurses is accredited as a
provider of nursing continuing professional development by the
American Nurses Credentialing Center's Commission on Accreditation.
Nurses who complete this activity and achieve a passing score will
receive 1 hour in nursing continuing professional development.
This activity has been approved by the American Board of Managed
Care Nursing for 1.0 contact hours toward CMCN recertification
This activity is supported by an educational grant from
NAMCP and/or this website does not
provide medical advice, diagnosis or treatment. NAMCP does not
endorse or imply endorsement of the content on any linked website.
This website is to be used as an informational resource. With any
health related concern, consult with your physician or healthcare
Click Here To Continue